ArticleCardiovascular diagnosis and therapy2025
The value of miRNA-29b in the diagnosis of myocardial infarction and the evaluation of cardiac function after myocardial infarction.
Article in Cardiovascular diagnosis and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: miRNA-29b affects angiogenesis and cardiac fibrosis, processes relevant to the pathophysiology of myocardial infarction (MI). This study aimed to investigate the accuracy of miRNA-29b in diagnosing acute myocardial infarction (AMI) and its association with postinfarction cardiac function. Methods: A total of 106 patients with AMI admitted to the Department of Cardiology of Hebei General Hospital between January 2023 and July 2024 were prospectively enrolled within 24 hours of symptom onset. Indicators including circulating miRNA-29b levels [detected via real-time quantitative polymerase chain reaction (RT-qPCR)], myocardial enzymes, vascular endothelial growth factor (VEGF), and tumor necrosis factor-α (TNF-α) were assessed at baseline. Cardiac function was assessed by echocardiography. Left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVEDs), and left ventricular posterior wall thickness at end-diastole (LVPWd) and end-systole (LVPWs) were also measured. Based on echocardiography, patients with AMI (n=106) were divided into an abnormal cardiac function (ACF) group (LVEF <50%; n=50) or a normal cardiac function (NCF) group (LVEF ≥50%; n=56). Thirty healthy participants were selected as the control group. Variables were compared with independent samples t-tests. Correlation and receiver operating characteristic (ROC) curve analyses were also conducted. Results: There was no significant differences in baseline demographic or clinical characteristics between the AMI and control groups; however, the control group, compared with the AMI group, had lower levels of low-density lipoprotein cholesterol (2.72±0.58 Conclusions: Blood miRNA-29b is lower in patients with AMI, particularly in those with impaired cardiac function. miRNA-29b demonstrates potential value in the diagnosis of AMI and the assessment of postinfarction cardiac function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.